Promising Safety and Efficacy Results from an Ongoing Phase 1/2 Study of Pembrolizumab in Combination with Blinatumomab in Patients (pts) with Relapsed or Refractory (R/R) Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Sandhu, Karamjeet S. [1 ]
Quy Huynh-Tran [1 ]
Cooper, Elise Elise [1 ]
Zhang, Jianying [2 ]
Palmer, Joycelynne [2 ]
Tsai, Ni-Chun [2 ]
Thomas, Sandra [3 ]
Robbins, Marjorie [3 ]
Aribi, Ahmed [1 ]
Salhotra, Amandeep [1 ]
Mei, Mathew [1 ]
Cai, Ji-Lian [4 ]
Spielberger, Ricardo [4 ]
Koller, Paul [1 ]
Aldoss, Ibrahim [1 ]
Stein, Anthony [1 ]
Marcucci, Guido [1 ]
Budde, L. Elizabeth [1 ]
机构：
[1] City Hope Natl Med Ctr, Hematol Hematopoiet Cell Transplantat, 1500 E Duarte Rd, Duarte, CA 91010 USA
[2] City Hope Natl Med Ctr, Computat & Quantitat Med BRI, 1500 E Duarte Rd, Duarte, CA 91010 USA
[3] City Hope Natl Med Ctr, Clin Translat Program Dev, 1500 E Duarte Rd, Duarte, CA 91010 USA
[4] Kaiser Permanente BMT Program, Los Angeles, CA USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷
关键词：
ALL; acute lymphoblastic leukemia; blinatumomab; pembrolizumab;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ALL-440
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of inotuzumab ozogamicin (InO) in older patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) enrolled in the phase 3 INO-VATE trial.
    Jabbour, Elias
    Advani, Anjali S.
    Stelljes, Matthias
    Stock, Wendy
    Liedtke, Michaela
    Gokbuget, Nicola
    Martinelli, Giovanni
    O'Brien, Susan Mary
    Wang, Kongming
    Wang, Tao
    Paccagnella, M. Luisa
    Sleight, Barbara
    Vandendries, Erik
    DeAngelo, Daniel J.
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison
    Faderl, Stefan
    Jain, Nitin
    O'Brien, Susan Mary
    Thomas, Deborah A.
    Ravandi, Farhad
    Jabbour, Elias
    Pierce, Sherry
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [43] Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study
    Webster, Jonathan Allen
    Luskin, Marlise R.
    Rimando, Joseph
    Blackford, Amanda
    Zeidan, Amer M.
    Sharon, Elad
    Streicher, Howard
    DeAngelo, Daniel J.
    Luznik, Leo
    Gojo, Ivana
    BLOOD, 2023, 142
  • [44] Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL).
    Topp, Max S.
    Stelljes, Matthias
    Zugmaier, Gerhard
    Barnette, Phillip
    Heffner, Leonard T.
    Trippett, Tanya M.
    Bargou, Ralf C.
    Holland, Chris
    Benjamin, Jonathan
    Litzow, Mark Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Blinatumomab in Combination with Immune Checkpoint Inhibitors of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Preliminary Results of a Phase I Study
    Webster, Jonathan
    Luskin, Marlise R.
    Prince, Gabrielle T.
    DeZern, Amy E.
    DeAngelo, Daniel J.
    Levis, Mark J.
    Blackford, Amanda
    Sharon, Elad
    Streicher, Howard
    Luznik, Leo
    Gojo, Ivana
    BLOOD, 2018, 132
  • [46] Results of a phase I study of clofarabine (CLO) plus cyclophosphamide (CY) in adult patients (pts) with relapsed and/or refractory acute lymphoblastic leukemia (ALL)
    Faderl, S.
    Thomas, D. A.
    Gandhi, V.
    Huang, X.
    Borthakur, G.
    O'Brien, S.
    Ravandi, F.
    Plunkett, W.
    Bretz, J. L.
    Kantarjian, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] EFFECTS OF THE BITE® ANTIBODY BLINATUMOMAB ON MOLECULAR RESPONSE IN A PHASE 2 OPEN-LABEL, MULTICENTER CONFIRMATORY STUDY IN RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL)
    Goekbuget, N.
    Brueggemann, M.
    Topp, M. S.
    Stein, A. S.
    Bargou, R. C.
    Dombret, H.
    Ribera, J. M.
    Foa, R.
    Zugmaier, G.
    Holland, C.
    Maniar, T.
    Huber, B.
    Nagorsen, D.
    Kantarjian, H. M.
    HAEMATOLOGICA, 2014, 99 : 508 - 509
  • [48] Long Term Follow-up on Phase 2 Study on the Efficacy and Safety of Blinatumomab in Adult Patients with Relapsed Refractory B-Precursor Acute Lymphoblastic Leukemia
    Aboudalle, Iman
    Kantarjian, Hagop M.
    Short, Nicholas J.
    Ravandi, Farhad
    Sasaki, Koji
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Cortes, Jorge E.
    Benton, Christopher B.
    Issa, Ghayas C.
    Khouri, Maria
    Nasnas, Patrice
    O'Brien, Susan M.
    Jabbour, Elias J.
    BLOOD, 2018, 132
  • [49] Results of A Phase I Study of Ruxolitinib in Patients (pts) with Relapsed/Refractory Acute Leukemia
    Pemmaraju, Naveen
    Kantarjian, Hagop M.
    O'Brien, Susan
    Kadia, Tapan M.
    Cortes, Jorge E.
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    Koller, Charles Asa
    Dellasala, Sara E.
    Pierce, Sherry A.
    Burton, Elizabeth M.
    Verstovsek, Srdan
    BLOOD, 2012, 120 (21)
  • [50] BUDGET IMPACT ANALYSIS ON BLINATUMOMAB FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (R/R BCP-ALL)
    Zhao, J.
    Jin, G.
    Yang, L.
    VALUE IN HEALTH, 2022, 25 (07) : S404 - S405
12345